Skip to main content
Medical information Clinical review pending

Neurology

Acetylcholine Receptor AChR Modulating Antibody Test

This test helps diagnose Myasthenia Gravis, an autoimmune neuromuscular disorder causing muscle weakness and fatigue. It detects antibodies affecting acetylcholine receptors.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
2 mL (0.5 mL minimum) serum collected in a Red Top tube (no additive). Do not use SST gel barrier tubes.
Results
Confirm with the laboratory before booking.
Preparation
Avoid general anaesthetic or muscle relaxant drugs 24 hours prior to sample collection. A completed Test Send Out Consent Form (Form 35) is required.
Test priceKSh 48,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the Acetylcholine Receptor AChR Modulating Antibody Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Muscle weakness worsening with activity
  • ✓Unusual fatigue
  • ✓Drooping eyelids (ptosis)
  • ✓Difficulty swallowing
  • ✓Difficulty speaking
  • ✓Suspected Myasthenia Gravis
  • ✓Family history of autoimmune diseases
02

In plain language

What this test helps you understand

This test is used to aid in the diagnosis of Myasthenia Gravis, an autoimmune neuromuscular disorder. It helps identify the presence of antibodies that interfere with acetylcholine receptors at the neuromuscular junction.
The Acetylcholine Receptor (AChR) Modulating Antibody Test is a key diagnostic tool used to identify Myasthenia Gravis (MG), a chronic autoimmune condition affecting the neuromuscular junction. This test is important for patients experiencing symptoms like muscle weakness and fatigue. Detecting these specific antibodies helps healthcare providers confirm a diagnosis and develop appropriate management strategies.

This test specifically looks for antibodies that interfere with the function of acetylcholine receptors, which are essential for muscle contraction. The presence of these antibodies is strongly associated with Myasthenia Gravis.

If you are experiencing symptoms such as muscle weakness that worsens with activity, unusual fatigue, drooping eyelids (ptosis), or difficulties with swallowing or speaking, discuss this test with your doctor. A family history of autoimmune diseases may also be a relevant factor.

An accurate diagnosis through this test allows for timely and effective treatment, helping to manage symptoms and improve quality of life. It also aids in monitoring how well treatment is working over time.

Your healthcare provider will interpret your test results in the context of your symptoms and medical history. A positive result indicates the presence of AChR modulating antibodies, supporting a diagnosis of Myasthenia Gravis. Discuss the results and any necessary follow-up steps with your doctor.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationAvoid general anaesthetic or muscle relaxant drugs 24 hours prior to sample collection. A completed Test Send Out Consent Form (Form 35) is required.
Sample2 mL (0.5 mL minimum) serum collected in a Red Top tube (no additive). Do not use SST gel barrier tubes.
MethodologyConfirm with the laboratory before booking.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test detects specific antibodies associated with Myasthenia Gravis. A negative result does not completely rule out the condition, as some patients may have antibodies not detected by this specific test or may have other forms of neuromuscular disorders. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Myasthenia Gravis (MG) is a chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue that worsens with activity and improves with rest.
These are antibodies produced by the immune system that interfere with the function of acetylcholine receptors at the neuromuscular junction, leading to muscle weakness in Myasthenia Gravis.
Symptoms like muscle weakness (especially worsening with use), fatigue, drooping eyelids, difficulty swallowing, or speaking may indicate Myasthenia Gravis and warrant discussion with your doctor about this test.
A blood sample (serum) is required. It should be collected in a specific type of tube (Red Top, no additive) and sent to the lab under appropriate conditions (refrigerated or frozen).
A positive result indicates the presence of AChR modulating antibodies, which strongly supports a diagnosis of Myasthenia Gravis. Your doctor will interpret this result alongside your clinical presentation.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp